Metsera Inc (MTSR)

$70.50 -0.25 (-0.35%)
Market Cap 7.42B
Revenue (ttm) 0.00
Net Income (ttm) -209.13M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 27,908,900
Avg Vol 3,697,740
Day's Range N/A - N/A
Shares Out 105.29M
Stochastic %K 43%
Beta N/A
Analysts Strong Sell
Price Target $55.75

Company Profile

Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity, as well as MET-815i to reduce weight or prevents weight gain. The company was incorporated in 2022 and is based in New York, N...

Industry: Biotechnology
Sector: Healthcare
Phone: 212 784 6595
Website: metsera.com
Address:
3 World Trade Center, 175 Greenwich Street, New York, United States
InvestorCG
InvestorCG Feb. 3 at 2:10 PM
$NMRA $PFE $MTSR weight loss drug data was meh. Let's hope Pinto (was board member of $MTSR) has a better outcome with ours. One less competitor to be worried about.
0 · Reply
rick4u
rick4u Jan. 29 at 7:11 PM
$MTSR any news from pfe?
0 · Reply
himsssss
himsssss Jan. 28 at 12:19 AM
Another bone I'll throw after Metsera win, is Asceltis. If your brokerage supports international trading look up Asceltis (HKEX specifically), LOAD THE BOAT ON HK1672. I brought up Asceltis back at $400M market cap now its at $1.7B. Do the DD yourself, they are lined up for a BP to take em out. $VKTX $GPCR $MTSR $ALT
2 · Reply
Zkoko_Bio
Zkoko_Bio Jan. 21 at 3:29 AM
$ALT precipitation is the worst ! What does $PFE really get from $MTSR ? They should've waited to get $ALT 💪 Still time !
1 · Reply
JFais
JFais Jan. 13 at 11:27 PM
$NVO on the hunt for obesity deals after losing out on $MTSR Combining with novel MOA for GLP-1 off ramp & to lower dose/AEs seem like the obvious play $ARWR $WVE
2 · Reply
himsssss
himsssss Jan. 13 at 3:13 PM
$VKTX $GPCR $MTSR Bulls are in denial everyday.
0 · Reply
InvestorCG
InvestorCG Jan. 12 at 5:59 PM
$NMRA $MTSR $NVO $PFE Metserra buyout headlines day one of JPM. Sure seems like we should be a highlight as well. Get to it. https://endpoints.news/jpm26-day-1-at-the-jp-morgan-healthcare-conference/?u=b678e863-aede-434f-bf88-fa4c122e5b5c&s=email&c=79153abc-466c0241-d2a827c0&utm_medium=email&utm_campaign=2364%20-%20AbbVie%20joins%20PD-1xVEGF%20bispecific%20contest%20Lilly%20Nvidia%20sign%20another%20collab%20Basic&utm_content=2364%20-%20AbbVie%20joins%20PD-1xVEGF%20bispecific%20contest%20Lilly%20Nvidia%20sign%20another%20collab%20Basic+CID_7fdf98b4b3c1fb8795fdd364e2c646f3&utm_source=ENDPOINTS%20emails&utm_term=JPM26%20live%20blog%20day%201%20Novo%20CEO%20has%20no%20regrets%20about%20Metsera%20showdown
0 · Reply
InvestorCG
InvestorCG Jan. 9 at 2:33 PM
$NMRA Interesting tidbit. Our President, Joshua Pinto, was on the board of directors of $MTSR. Look what happened to them last month. HUGE buyout. It is important that Pinto sounds real enthusiastic when talking about our obesity drug, in light of the buyouts occurring with $PFE $NVO $LLY
0 · Reply
himsssss
himsssss Dec. 30 at 6:51 PM
$VKTX Stop the nonsense, its not at this price level because this ticker is manipulated by shorts or funds. I've been blocked for calling things as is and have been right about it this whole time. No BP is going to buyout this out of date pipeline with thin data. Oral pill went from hype to dull real quick after p2 data. Companies that didn't cut corners, and kept working have now caught up or went past this ticker. $GPCR being valued about $1B more isn't because of manipulation. $MTSR being bought out at $10B while VKTX struggles to hold $4B isnt because of poor choices by BP.
3 · Reply
NadirNet
NadirNet Dec. 27 at 4:52 AM
$MTSR Trading dynamics suggest reliability now matters more than momentum bursts. Balance‑sheet flexibility may prove significant. Execution consistency is the fastest path to confidence rebuilding. Momentum becomes sustainable only when delivery keeps pace.
0 · Reply
Latest News on MTSR
Pfizer Completes Acquisition of Metsera

Nov 13, 2025, 11:26 AM EST - 2 months ago

Pfizer Completes Acquisition of Metsera

PFE

Metsera shareholders vote for $10 billion acquisition by Pfizer

Nov 13, 2025, 9:18 AM EST - 2 months ago

Metsera shareholders vote for $10 billion acquisition by Pfizer

PFE

Instacart Up on Earnings Beat; Metsera Down on Takeover Battle | Stock Movers

Nov 10, 2025, 4:28 PM EST - 3 months ago

Instacart Up on Earnings Beat; Metsera Down on Takeover Battle | Stock Movers

CART

Pfizer to buy Metsera in deal worth up to $10 billion

Nov 10, 2025, 10:30 AM EST - 3 months ago

Pfizer to buy Metsera in deal worth up to $10 billion

PFE

Pfizer CEO: Metsera deal gives us 'one of the most exciting, advanced portfolios' in obesity drugs

Nov 10, 2025, 10:21 AM EST - 3 months ago

Pfizer CEO: Metsera deal gives us 'one of the most exciting, advanced portfolios' in obesity drugs

PFE

Pfizer Is Buying Weight-Loss Drugmaker Metsera. Why Novo Nordisk Is the Winner.

Nov 10, 2025, 7:32 AM EST - 3 months ago

Pfizer Is Buying Weight-Loss Drugmaker Metsera. Why Novo Nordisk Is the Winner.

NVO PFE

Monday.Com, Metsera, Profrac Holding And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Nov 10, 2025, 6:18 AM EST - 3 months ago

Monday.Com, Metsera, Profrac Holding And Other Big Stocks Moving Lower In Monday's Pre-Market Session

ACDC MNDY

Novo Nordisk Shares Rise After Withdrawal from Metsera Takeover Battle

Nov 10, 2025, 4:38 AM EST - 3 months ago

Novo Nordisk Shares Rise After Withdrawal from Metsera Takeover Battle

NVO

Novo Nordisk shares rise after dropping Metsera bid

Nov 10, 2025, 3:05 AM EST - 3 months ago

Novo Nordisk shares rise after dropping Metsera bid

NVO

Novo Nordisk will not increase its proposal to acquire Metsera, Inc.

Nov 8, 2025, 3:19 AM EST - 3 months ago

Novo Nordisk will not increase its proposal to acquire Metsera, Inc.

NVO

Pfizer has agreed to buy weight-loss drug startup Metsera in a deal that could be worth more than $10 billion, besting rival Novo Nordisk following a heated bidding war

Nov 7, 2025, 10:07 PM EST - 3 months ago

Pfizer has agreed to buy weight-loss drug startup Metsera in a deal that could be worth more than $10 billion, besting rival Novo Nordisk following a heated bidding war

PFE

Pfizer and Metsera Enter into Merger Agreement Amendment; Metsera's Board of Directors Reaffirms Support of Merger with Pfizer

Nov 7, 2025, 9:32 PM EST - 3 months ago

Pfizer and Metsera Enter into Merger Agreement Amendment; Metsera's Board of Directors Reaffirms Support of Merger with Pfizer

PFE

Pfizer sweetens offer for Metsera in bidding war against Novo, Bloomberg News reports

Nov 7, 2025, 7:59 PM EST - 3 months ago

Pfizer sweetens offer for Metsera in bidding war against Novo, Bloomberg News reports

PFE

Novo CEO says its bid for Metsera is higher

Nov 6, 2025, 2:23 PM EST - 3 months ago

Novo CEO says its bid for Metsera is higher

NVO

What is Metsera, the target in Pfizer's and Novo Nordisk's bidding war?

Nov 6, 2025, 12:01 PM EST - 3 months ago

What is Metsera, the target in Pfizer's and Novo Nordisk's bidding war?

NVO PFE

Pfizer To Raise Metsera Bid After Court Denies Attempt To Block Rival Deal

Nov 6, 2025, 11:40 AM EST - 3 months ago

Pfizer To Raise Metsera Bid After Court Denies Attempt To Block Rival Deal

PFE

Metsera weighs rival bids from Pfizer, Novo in $10 billion obesity drug battle

Nov 6, 2025, 8:49 AM EST - 3 months ago

Metsera weighs rival bids from Pfizer, Novo in $10 billion obesity drug battle

PFE

Wall Street Breakfast Podcast: Government Shutdown Hits New Altitude

Nov 6, 2025, 6:29 AM EST - 3 months ago

Wall Street Breakfast Podcast: Government Shutdown Hits New Altitude

NVO PFE WBD

Metsera Issues Statement in Response to Litigation Ruling

Nov 5, 2025, 7:17 PM EST - 3 months ago

Metsera Issues Statement in Response to Litigation Ruling

Expect Pfizer bid to beat Novo for Metsera, says BMO's Evan David Seigerman

Nov 5, 2025, 6:02 PM EST - 3 months ago

Expect Pfizer bid to beat Novo for Metsera, says BMO's Evan David Seigerman

PFE

Pfizer preparing to raise its bid for Metsera, WSJ reports

Nov 5, 2025, 5:02 PM EST - 3 months ago

Pfizer preparing to raise its bid for Metsera, WSJ reports

PFE

Pfizer is preparing to sweeten its offer again for Metsera, the weight-loss drug startup at the center of a bidding war that also involves Novo Nordisk

Nov 5, 2025, 4:52 PM EST - 3 months ago

Pfizer is preparing to sweeten its offer again for Metsera, the weight-loss drug startup at the center of a bidding war that also involves Novo Nordisk

NVO PFE

Delaware judge says she will not block Metsera from ending Pfizer deal

Nov 5, 2025, 4:20 PM EST - 3 months ago

Delaware judge says she will not block Metsera from ending Pfizer deal

PFE

Pfizer says it removed some conditions from its Metsera bid

Nov 5, 2025, 2:19 PM EST - 3 months ago

Pfizer says it removed some conditions from its Metsera bid

PFE

The Multi-Billion-Dollar Battle For Metsera's Obesity Drugs

Nov 5, 2025, 1:20 PM EST - 3 months ago

The Multi-Billion-Dollar Battle For Metsera's Obesity Drugs

Healthy Returns: What to know about Pfizer and Novo Nordisk's bidding war over obesity biotech Metsera

Nov 5, 2025, 10:07 AM EST - 3 months ago

Healthy Returns: What to know about Pfizer and Novo Nordisk's bidding war over obesity biotech Metsera

NVO PFE

Novo Nordisk CEO Mike Doustdar on $10B Metsera bid, expanding use of obesity drugs

Nov 5, 2025, 9:20 AM EST - 3 months ago

Novo Nordisk CEO Mike Doustdar on $10B Metsera bid, expanding use of obesity drugs

NVO

Novo Nordisk CEO: Confident we will close Metsera deal

Nov 5, 2025, 5:39 AM EST - 3 months ago

Novo Nordisk CEO: Confident we will close Metsera deal

NVO

Novo, Pfizer Are Battling To Buy The Future Of Weight-Loss — But Viking Already Owns It

Nov 4, 2025, 3:04 PM EST - 3 months ago

Novo, Pfizer Are Battling To Buy The Future Of Weight-Loss — But Viking Already Owns It

PFE NVO

Pfizer, Novo Nordisk Intensify Fight For Metsera As Buyout Offers Continue To Climb

Nov 4, 2025, 2:45 PM EST - 3 months ago

Pfizer, Novo Nordisk Intensify Fight For Metsera As Buyout Offers Continue To Climb

NVO PFE

Why Metsera stock's 20% surge signals a fierce Pfizer-Novo Nordisk bidding war

Nov 4, 2025, 1:02 PM EST - 3 months ago

Why Metsera stock's 20% surge signals a fierce Pfizer-Novo Nordisk bidding war

Pfizer and Novo Nordisk both raise bids for Metsera

Nov 4, 2025, 12:18 PM EST - 3 months ago

Pfizer and Novo Nordisk both raise bids for Metsera

NVO PFE

Delaware judge does not see current need for court in Metsera bidding war between Pfizer and Novo

Nov 4, 2025, 11:29 AM EST - 3 months ago

Delaware judge does not see current need for court in Metsera bidding war between Pfizer and Novo

PFE

Metsera said it received a revised acquisition offer from Novo Nordisk that it called superior to Pfizer's bid

Nov 4, 2025, 9:58 AM EST - 3 months ago

Metsera said it received a revised acquisition offer from Novo Nordisk that it called superior to Pfizer's bid

NVO PFE

Metsera says Novo Nordisk's new bid for obesity drugmaker is ‘superior' to revised Pfizer offer

Nov 4, 2025, 9:40 AM EST - 3 months ago

Metsera says Novo Nordisk's new bid for obesity drugmaker is ‘superior' to revised Pfizer offer

NVO PFE

Novo Nordisk submits updated proposal to acquire Metsera, Inc.

Nov 4, 2025, 9:31 AM EST - 3 months ago

Novo Nordisk submits updated proposal to acquire Metsera, Inc.

NVO

Novo Nordisk, Pfizer sweeten bid for Metsera as bidding war heats up

Nov 4, 2025, 9:20 AM EST - 3 months ago

Novo Nordisk, Pfizer sweeten bid for Metsera as bidding war heats up

NVO PFE

Metsera Receives Amended Proposal from Novo Nordisk; Metsera Declares Novo Nordisk Amended Proposal "Superior"

Nov 4, 2025, 9:09 AM EST - 3 months ago

Metsera Receives Amended Proposal from Novo Nordisk; Metsera Declares Novo Nordisk Amended Proposal "Superior"

Novo Nordisk says Metsera bid won't raise antitrust issues

Nov 3, 2025, 12:04 PM EST - 3 months ago

Novo Nordisk says Metsera bid won't raise antitrust issues

NVO

Pfizer files second lawsuit against Novo Nordisk, Metsera in bidding war over obesity biotech

Nov 3, 2025, 11:39 AM EST - 3 months ago

Pfizer files second lawsuit against Novo Nordisk, Metsera in bidding war over obesity biotech

NVO PFE

Metsera Issues Statement in Response to Litigation

Nov 3, 2025, 11:02 AM EST - 3 months ago

Metsera Issues Statement in Response to Litigation

Pfizer Files Antitrust Suit to Block Novo Nordisk Acquisition of Metsera

Nov 3, 2025, 9:19 AM EST - 3 months ago

Pfizer Files Antitrust Suit to Block Novo Nordisk Acquisition of Metsera

NVO PFE

Pfizer files second lawsuit against Metsera, Novo Nordisk

Nov 3, 2025, 8:07 AM EST - 3 months ago

Pfizer files second lawsuit against Metsera, Novo Nordisk

NVO PFE

Heard on the Street: Novo Nordisk and Pfizer are showing some desperation in their gloves-off fight for the obesity-drug assets of Metsera

Nov 2, 2025, 5:30 AM EST - 3 months ago

Heard on the Street: Novo Nordisk and Pfizer are showing some desperation in their gloves-off fight for the obesity-drug assets of Metsera

NVO PFE

Pfizer has filed a lawsuit seeking to block Novo Nordisk from circumventing Pfizer's deal for weight-loss drug startup Metsera

Oct 31, 2025, 5:12 PM EDT - 3 months ago

Pfizer has filed a lawsuit seeking to block Novo Nordisk from circumventing Pfizer's deal for weight-loss drug startup Metsera

NVO PFE

Pfizer sues Metsera, Novo Nordisk over breach of merger deal

Oct 31, 2025, 4:43 PM EDT - 3 months ago

Pfizer sues Metsera, Novo Nordisk over breach of merger deal

NVO PFE

Pfizer gets US antitrust clearance for Metsera deal

Oct 31, 2025, 3:55 PM EDT - 3 months ago

Pfizer gets US antitrust clearance for Metsera deal

PFE

Pfizer Receives Early Clearance from U.S. Federal Trade Commission for Metsera Acquisition

Oct 31, 2025, 3:50 PM EDT - 3 months ago

Pfizer Receives Early Clearance from U.S. Federal Trade Commission for Metsera Acquisition

PFE

Pfizer could hold a Trump card in its bid for Metsera

Oct 31, 2025, 6:02 AM EDT - 3 months ago

Pfizer could hold a Trump card in its bid for Metsera

PFE

Mizuho's Holtz talks what is behind Novo's bid for Metsera

Oct 30, 2025, 6:20 PM EDT - 3 months ago

Mizuho's Holtz talks what is behind Novo's bid for Metsera

InvestorCG
InvestorCG Feb. 3 at 2:10 PM
$NMRA $PFE $MTSR weight loss drug data was meh. Let's hope Pinto (was board member of $MTSR) has a better outcome with ours. One less competitor to be worried about.
0 · Reply
rick4u
rick4u Jan. 29 at 7:11 PM
$MTSR any news from pfe?
0 · Reply
himsssss
himsssss Jan. 28 at 12:19 AM
Another bone I'll throw after Metsera win, is Asceltis. If your brokerage supports international trading look up Asceltis (HKEX specifically), LOAD THE BOAT ON HK1672. I brought up Asceltis back at $400M market cap now its at $1.7B. Do the DD yourself, they are lined up for a BP to take em out. $VKTX $GPCR $MTSR $ALT
2 · Reply
Zkoko_Bio
Zkoko_Bio Jan. 21 at 3:29 AM
$ALT precipitation is the worst ! What does $PFE really get from $MTSR ? They should've waited to get $ALT 💪 Still time !
1 · Reply
JFais
JFais Jan. 13 at 11:27 PM
$NVO on the hunt for obesity deals after losing out on $MTSR Combining with novel MOA for GLP-1 off ramp & to lower dose/AEs seem like the obvious play $ARWR $WVE
2 · Reply
himsssss
himsssss Jan. 13 at 3:13 PM
$VKTX $GPCR $MTSR Bulls are in denial everyday.
0 · Reply
InvestorCG
InvestorCG Jan. 12 at 5:59 PM
$NMRA $MTSR $NVO $PFE Metserra buyout headlines day one of JPM. Sure seems like we should be a highlight as well. Get to it. https://endpoints.news/jpm26-day-1-at-the-jp-morgan-healthcare-conference/?u=b678e863-aede-434f-bf88-fa4c122e5b5c&s=email&c=79153abc-466c0241-d2a827c0&utm_medium=email&utm_campaign=2364%20-%20AbbVie%20joins%20PD-1xVEGF%20bispecific%20contest%20Lilly%20Nvidia%20sign%20another%20collab%20Basic&utm_content=2364%20-%20AbbVie%20joins%20PD-1xVEGF%20bispecific%20contest%20Lilly%20Nvidia%20sign%20another%20collab%20Basic+CID_7fdf98b4b3c1fb8795fdd364e2c646f3&utm_source=ENDPOINTS%20emails&utm_term=JPM26%20live%20blog%20day%201%20Novo%20CEO%20has%20no%20regrets%20about%20Metsera%20showdown
0 · Reply
InvestorCG
InvestorCG Jan. 9 at 2:33 PM
$NMRA Interesting tidbit. Our President, Joshua Pinto, was on the board of directors of $MTSR. Look what happened to them last month. HUGE buyout. It is important that Pinto sounds real enthusiastic when talking about our obesity drug, in light of the buyouts occurring with $PFE $NVO $LLY
0 · Reply
himsssss
himsssss Dec. 30 at 6:51 PM
$VKTX Stop the nonsense, its not at this price level because this ticker is manipulated by shorts or funds. I've been blocked for calling things as is and have been right about it this whole time. No BP is going to buyout this out of date pipeline with thin data. Oral pill went from hype to dull real quick after p2 data. Companies that didn't cut corners, and kept working have now caught up or went past this ticker. $GPCR being valued about $1B more isn't because of manipulation. $MTSR being bought out at $10B while VKTX struggles to hold $4B isnt because of poor choices by BP.
3 · Reply
NadirNet
NadirNet Dec. 27 at 4:52 AM
$MTSR Trading dynamics suggest reliability now matters more than momentum bursts. Balance‑sheet flexibility may prove significant. Execution consistency is the fastest path to confidence rebuilding. Momentum becomes sustainable only when delivery keeps pace.
0 · Reply
FingerlessRage
FingerlessRage Dec. 24 at 12:50 PM
$MTSR I LIKE IT
1 · Reply
Thepatientone
Thepatientone Dec. 23 at 9:34 PM
$ALT BIC vs $AKRO , $ETNB , $MTSR , $MADRIG, $VKTX Altimmune is not “missing” anything. It has already cleared the Phase 3 gate and is now running a program that reflects modern regulatory thinking, not legacy dogma. None of the others have done such, no one.
2 · Reply
Tradinggraces17
Tradinggraces17 Dec. 23 at 8:49 PM
$ALT $ETNB $MDGL $MTSR $VKTX As we kick off Festivus 2025, I’d like to start with the Airing of Grievances. No one in VKTX gives a shit about ALT, and it being BIC. No one. That’s all, carry on.
3 · Reply
Thepatientone
Thepatientone Dec. 23 at 8:33 PM
$ALT BIC vs $AKERO, $ETNB , $MTSR , $MDGL , $VKTX and etc. Please mute parasites and leaches. Do your DD and think. Wegovy/Ozempic were approved for what? diabetes, the weight loss was a side effect and it is not a quality weight loss, muscle mass preservation is critical to long term health. FDA does not care about the margins, cares about safety, Pemvi is BIC, cares about titration so patients will stay on the drug, Pemvi is best in class, cares about side effects, Pemvi has none. BIC and Pemvi is for Mash resolution, which is BIC in just 24 weeks, Fibrosis non worsening is an FDA requirement not fibrosis clearance so BIC again. Then in addition you have the CV improvements and NITs showing BIC platform. Rely on facts only facts. In a matter of week/s you will be happy.
3 · Reply
judgeyoung2
judgeyoung2 Dec. 20 at 10:38 PM
$MTSR j
0 · Reply
Thepatientone
Thepatientone Dec. 20 at 5:45 PM
$ALT BIC VS $AKRO , $89BIO, $MTSR , $MDGL , $VKTX Quality of weight loss: Yes (likely), subject to continued validation MASH resolution at 24 weeks: Yes (strong case) Cardiovascular health: Not proven yet (credible thesis, but still optionality) Tolerability / AE / discontinuations: Yes (strong case) NITs: Yes (strong case for coherence + durability) The one thing I’d add (even though you didn’t ask) If you’re comparing “superior treatment” in the full MASH regulatory sense, the open question remains: Biopsy-confirmed fibrosis improvement in a Phase 3-sized dataset at 48–52 weeks (and durability beyond)
0 · Reply
Thepatientone
Thepatientone Dec. 20 at 2:47 PM
$ALT BIC vs $AKERO, $ETNB , $MTSR , $MDGL , $VKTX - AI read and NITs will be the standard and $ALT is leading. KOLs are not wrong when they say biopsy can miss or misclassify disease. 1️⃣ Sampling error (the biggest problem) A biopsy samples ~1/50,000 of the liver Fibrosis and inflammation are heterogeneous One core can show F2, another F3 or F1 in the same patient Studies show: 20–30% discordance in fibrosis staging between two biopsy samples from the same liver Inter-reader variability even among expert pathologists 👉 This means biopsy can both overestimate and underestimate response. 2️⃣ Noise overwhelms signal in short trials Fibrosis remodeling is slow 24–52 weeks is often borderline too short to see clean stage shifts A true biological improvement may not cross the ≥1-stage threshold because of: Baseline misclassification Borderline staging Patchy regression This is why KOLs often say: “The drug worked, but the biopsy couldn’t see it.”
1 · Reply
devd7
devd7 Dec. 12 at 6:06 PM
$WVE well if it’s 10 billion like $MTSR then price is $60 but still only in phase 1 so how are they raising the price?
0 · Reply
Discovergems
Discovergems Dec. 9 at 5:08 PM
VKTX Looks like $PFE is looking for more assets. They might have made huge mistake with $MTSR deal. Why would you go out do smaller deals when you just bought a company just to use it as springboard for all Obesity related developments efforts.
0 · Reply
inspector_gadget86
inspector_gadget86 Dec. 8 at 3:50 PM
$MTSR is everyone just out of their shares and money here ????
0 · Reply
free2dream
free2dream Dec. 8 at 3:37 PM
$GPCR $10B for $MTSR , we are at $3.9B , hold your shares this will get a takeover bid !
0 · Reply
free2dream
free2dream Dec. 8 at 3:18 PM
$GPCR $MTSR 10B , $GPCR is still half that , keep your shares !
0 · Reply